Human retinal pigment epithelial cell therapy

Drug Profile

Human retinal pigment epithelial cell therapy

Alternative Names: ACT hESC-RPE; ASP7317; hESC-derived RPE; hRPE cell therapy; Human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells - Astellas; MA09-hRPE; RPE cell therapy - Astellas

Latest Information Update: 15 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Advanced Cell Technology
  • Developer Astellas Pharma; CHA Bio & Diostech
  • Class Eye disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stargardt disease
  • New Molecular Entity No

Highest Development Phases

  • Phase II Stargardt disease
  • Phase I/II Age-related macular degeneration
  • Preclinical Degenerative myopia

Most Recent Events

  • 25 Jul 2017 Astellas withdraws prior to enrolment the phase II PORTRAY trial in Age-related macular degeneration in USA (NCT02563782)
  • 09 Jun 2017 Astellas Pharma plans a phase I/II trial for Age-related macular degeneration (NCT03178149)
  • 30 May 2017 Astellas plans a phase I/II trial for Macular degeneration (NCT03167203)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top